from mercola.com: There are currently two HPV vaccines on the market, but if there was any regard for sound scientific evidence, neither would be promoted as heavily as they are. The first, Gardasil, was licensed by the US Food and Drug Administration (FDA) in 2006. It is now recommended as a routine vaccination for girls and women between the ages of 9-26 in the US. On October 25, 2011, the CDC’s Advisory Committee on Immunization Practices also voted to recommend giving the HPV vaccine to males between the ages of 11 and 21. The second HPV vaccine, Cervarix, was licensed in 2009. Were it to be discovered that the HPV vaccine, in fact, does not effectively prevent cancer, then young women (and now boys) are being exposed to clearly unacceptable health risks. And that’s precisely what a recent study has concluded. Review of HPV Trials Conclude Effectiveness is Still Completely Unproven. Published online on September 24, a systematic review of pre- and post-licensure trials of the HPV vaccine by a Canadian team shows that its effectiveness is not only overstated (through the use of selective reporting or “cherry picking” data) but also completely unproven. The summary states it quite clearly:

“We carried out a systematic review of HPV vaccine pre- and post-licensure trials to assess the evidence of their effectiveness and safety. We find that HPV vaccine clinical trials design, and data interpretation of both efficacy and safety outcomes, were largely inadequate. Additionally, we note evidence of selective reporting of results from clinical trials (i.e., exclusion of vaccine efficacy figures related to study subgroups in which efficacy might be lower or even negative from peer-reviewed publications). Given this, the widespread optimism regarding HPV vaccines long-term benefits appears to rest on a number of unproven assumptions (or such which are at odd with factual evidence) and significant misinterpretation of available data. For example, the claim that HPV vaccination will result in approximately 70% reduction of cervical cancers is made despite the fact that the clinical trials data have not demonstrated to date that the vaccines have actually prevented a single case of cervical cancer (let alone cervical cancer death), nor that the current overly optimistic surrogate marker-based extrapolations are justified. Likewise, the notion that HPV vaccines have an impressive safety profile is only supported by highly flawed design of safety trials and is contrary to accumulating evidence from vaccine safety surveillance databases and case reports which continue to link HPV vaccination to serious adverse outcomes (including death and permanent disabilities). We thus conclude that further reduction of cervical cancers might be best achieved by optimizing cervical screening (which carries no such risks) and targeting other factors of the disease rather than by the reliance on vaccines with questionable efficacy and safety profiles.”